National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2019

Three vaccines are recommended by the Advisory Committee on Immunization Practices (ACIP) for routine vaccination of adolescents aged 11-12 years to protect against 1) pertussis; 2) meningococcal disease caused by types A, C, W, and Y; and 3) human papillomavirus (HPV)-associated cancers (1). At age 16 years, a booster dose of quadrivalent meningococcal conjugate vaccine (MenACWY) is recommended. Persons aged 16-23 years can receive serogroup B meningococcal vaccine (MenB), if determined to be appropriate through shared clinical decision-making. CDC analyzed data from the 2019 National Immunization Survey-Teen (NIS-Teen) to estimate vaccination coverage among adolescents aged 13-17 years in the United States.* Coverage with ≥1 dose of HPV vaccine increased from 68.1% in 2018 to 71.5% in 2019, and the percentage of adolescents who were up to date† with the HPV vaccination series (HPV UTD) increased from 51.1% in 2018 to 54.2% in 2019. Both HPV vaccination coverage measures improved among females and males. An increase in adolescent coverage with ≥1 dose of MenACWY (from 86.6% in 2018 to 88.9% in 2019) also was observed. Among adolescents aged 17 years, 53.7% received the booster dose of MenACWY in 2019, not statistically different from 50.8% in 2018; 21.8% received ≥1 dose of MenB, a 4.6 percentage point increase from 17.2% in 2018. Among adolescents living at or above the poverty level,§ those living outside a metropolitan statistical area (MSA)¶ had lower coverage with ≥1 dose of MenACWY and with ≥1 HPV vaccine dose, and a lower percentage were HPV UTD, compared with those living in MSA principal cities. In early 2020, the coronavirus disease 2019 (COVID-19) pandemic changed the way health care providers operate and provide routine and essential services. An examination of Vaccines for Children (VFC) provider ordering data showed that vaccine orders for HPV vaccine; tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap); and MenACWY decreased in mid-March when COVID-19 was declared a national emergency (Supplementary Figure 1, https://stacks.cdc.gov/view/cdc/91795). Ensuring that routine immunization services for adolescents are maintained or reinitiated is essential to continuing progress in protecting persons and communities from vaccine-preventable diseases and outbreaks.

[1]  E. Meites,et al.  Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated Recommendations of the Advisory Committee on Immunization Practices. , 2016, MMWR. Morbidity and mortality weekly report.

[2]  Kristen M J Azar,et al.  Disparities In Outcomes Among COVID-19 Patients In A Large Health Care System In California. , 2020, Health affairs.

[3]  Thomas J. Stickrath,et al.  Ohio Department of Rehabilitation and Correction , 1997 .

[4]  Kevin A. Henry,et al.  HPV Vaccination Coverage Among US Teens Across the Rural-Urban Continuum. , 2019, The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association.

[5]  S. Stokley,et al.  National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2018 , 2019, MMWR. Morbidity and mortality weekly report.

[6]  S. Allen,et al.  Fentanyl-contaminated drugs and non-fatal overdose among people who inject drugs in Baltimore, MD , 2018, Harm Reduction Journal.

[7]  Anne Kimball,et al.  Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility — King County, Washington, March 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[8]  Manish M Patel,et al.  Characteristics of Adult Outpatients and Inpatients with COVID-19 — 11 Academic Medical Centers, United States, March–May 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[9]  J. Zucker,et al.  Notes from the Field: Rebound in Routine Childhood Vaccine Administration Following Decline During the COVID-19 Pandemic — New York City, March 1–June 27, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[10]  M. Hellard,et al.  Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. , 2014, International journal of epidemiology.

[11]  D. Rhubart,et al.  Differences in Human Papillomavirus Vaccination Among Adolescent Girls in Metropolitan Versus Non-metropolitan Areas: Considering the Moderating Roles of Maternal Socioeconomic Status and Health Care Access , 2016, Maternal and Child Health Journal.

[12]  T. S. Jones,et al.  Community-based opioid overdose prevention programs providing naloxone - United States, 2010. , 2012, MMWR. Morbidity and mortality weekly report.

[13]  A. Kempe,et al.  Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2017 , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  C. Beckwith,et al.  Spotlight on Jails: COVID-19 Mitigation Policies Needed Now , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  James M. Blum,et al.  Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 — Georgia, March 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[16]  Y. Tie,et al.  Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[17]  Kevin A. Henry,et al.  Area-based socioeconomic factors and Human Papillomavirus (HPV) vaccination among teen boys in the United States , 2017, BMC Public Health.

[18]  D. McCormick,et al.  COVID-19 in Prisons and Jails in the United States. , 2020, JAMA internal medicine.

[19]  Alex H. Kral,et al.  Overdose Prevention and Naloxone Prescription for Opioid Users in San Francisco , 2010, Journal of Urban Health.

[20]  Jessica S. Brown,et al.  Characteristics of Persons Who Died with COVID-19 - United States, February 12-May 18, 2020. , 2020, MMWR. Morbidity and mortality weekly report.

[21]  S. Lindstrom,et al.  First Case of 2019 Novel Coronavirus in the United States , 2020, The New England journal of medicine.

[22]  S. Bird,et al.  Scotland's National Naloxone Programme , 2019, The Lancet.

[23]  Beau B. Bruce,et al.  Characteristics Associated with Hospitalization Among Patients with COVID-19 — Metropolitan Atlanta, Georgia, March–April 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[24]  Al Ozonoff,et al.  Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis , 2013, BMJ.

[25]  D. Holtzman,et al.  Syringe Service Programs for Persons Who Inject Drugs in Urban, Suburban, and Rural Areas - United States, 2013. , 2015, MMWR. Morbidity and mortality weekly report.

[26]  A. Spaulding,et al.  Mass Testing for SARS-CoV-2 in 16 Prisons and Jails — Six Jurisdictions, United States, April–May 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[27]  Michelle Banks,et al.  Provision of Pediatric Immunization Services During the COVID-19 Pandemic: an Assessment of Capacity Among Pediatric Immunization Providers Participating in the Vaccines for Children Program — United States, May 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[28]  L. Maruschak,et al.  Medical problems of state and federal prisoners and jail inmates, 2011-12 , 2015 .

[29]  T. Selden,et al.  COVID-19 And Racial/Ethnic Disparities In Health Risk, Employment, And Household Composition. , 2020, Health affairs.

[30]  Catherine M. Brown,et al.  COVID-19 in Correctional and Detention Facilities - United States, February-April 2020. , 2020, MMWR. Morbidity and mortality weekly report.

[31]  J. Tate,et al.  Serial Laboratory Testing for SARS-CoV-2 Infection Among Incarcerated and Detained Persons in a Correctional and Detention Facility — Louisiana, April–May 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[32]  N. Krieger,et al.  Structural racism and health inequities in the USA: evidence and interventions , 2017, The Lancet.

[33]  N. Thakur,et al.  The Structural and Social Determinants of the Racial/Ethnic Disparities in the U.S. COVID-19 Pandemic. What’s Our Role? , 2020, American journal of respiratory and critical care medicine.

[34]  Kristen M. Fedak,et al.  Update: COVID-19 Among Workers in Meat and Poultry Processing Facilities ― United States, April–May 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[35]  E. Topol,et al.  Prevalence of Asymptomatic SARS-CoV-2 Infection , 2021, Annals of Internal Medicine.

[36]  S. Stokley,et al.  National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2017 , 2018, MMWR. Morbidity and mortality weekly report.

[37]  Elyse O Kharbanda,et al.  Effects of the COVID-19 Pandemic on Routine Pediatric Vaccine Ordering and Administration - United States, 2020. , 2020, MMWR. Morbidity and mortality weekly report.

[38]  Buffalo,et al.  Syringe Exchange Programs—United States , 2007 .

[39]  T. S. Jones,et al.  Opioid Overdose Prevention Programs Providing Naloxone to Laypersons — United States, 2014 , 2015, MMWR. Morbidity and mortality weekly report.

[40]  D. D. Ingram,et al.  NCHS urban-rural classification scheme for counties. , 2012, Vital and health statistics. Series 2, Data evaluation and methods research.

[41]  K. Poehling,et al.  Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[42]  L. Epstein,et al.  Facility-Wide Testing for SARS-CoV-2 in Nursing Homes — Seven U.S. Jurisdictions, March–June 2020 , 2020, MMWR. Morbidity and mortality weekly report.